Skip to Content

Posts tagged with "Drug Development"

  • Drug Development

    Drugs, Airplanes, and Radios

    Wavefunction has a good post in response to this article, which speculates “If we designed airplanes the way we design drugs. . .” I think the original article is worth reading, but some – perhaps many – of its points are arguable. For example: Every drug that fails in a clinical trial or after it… Read More
  • Drug Assays

    Riding to the Rescue of Rhodanines

    There’s a new paper coming to the defense of rhodanines, a class of compound that has been described as “polluting the scientific literature”. Industrial drug discovery people tend to look down on them, but they show up a lot, for sure. This new paper starts off sounding like a call to arms for rhodanine fans… Read More
  • Cardiovascular Disease

    Pushing Onwards with CETP: The Big Money and the Big Risks

    Remember torcetrapib? Pfizer always will. The late Phase III failure of that CETP inhibitor wiped out their chances for an even bigger HDL-raising follow-up to LDL-lowering Lipitor, the world’s biggest drug, and changed the future of the company in ways that are still being played out. But CETP inhibition still makes sense, biochemically. And… Read More
  • Drug Development

  • Academia (vs. Industry)

    Francis Collins Speaks

    With all the recent talk about the NIH’s translational research efforts, and the controversy about their drug screening efforts, this seems like a good time to note this interview with Francis Collins over at BioCentury TV. (It’s currently the lead video, but you’ll be able to find it in their “Show Guide” afterwards a… Read More
  • Drug Development

    A Note to Andy Grove

    Readers will recall my occasional pieces on Intel legend Andy Grove’s idea for drug discovery. (The first one wasn’t too complimentary; the second was a bit more neutral). You always wonder, when you have a blog, if the people you’re writing about have a chance to see what you’ve said – well, in this case… Read More
  • Drug Development

    Harvard to the Rescue

    Harvard is announcing a big initiative in systems biology, which is an interdisciplinary opportunity if there ever was one. The Initiative in Systems Pharmacology is a signature component of the HMS Program in Translational Science and Therapeutics. There are two broad goals: first, to increase significantly our knowledge of human disease mechanism… Read More
  • Cancer

    Too Many Cancer Drugs? Too Few? About Right?

    According to Bruce Booth (@LifeSciVC on Twitter), Ernst & Young have estimated the proportion of drugs in the clinic in the US that are targeting cancer. Anyone want to pause for a moment to make a mental estimate of their own? Well, I can tell you that I was a bit low. The E&Y number… Read More
  • Drug Assays

    Different Drug Companies Make Rather Different Compounds

    Now here’s a paper, packed to the edges with data, on what kinds of drug candidate compounds different companies produce. The authors assembled their list via the best method available to outsiders: they looked at what compounds are exemplified in patent filings What they find is that over the 2000-2010 period that not much change… Read More
  • Academia (vs. Industry)

    How Many New Drug Targets Aren’t Even Real?

    So, are half the interesting new results in the medical/biology/med-chem literature impossible to reproduce? I linked earlier this year to an informal estimate from venture capitalist Bruce Booth, who said that this was his (and others’) experience in the business. Now comes a new study from Bayer Pharmaceuticals that helps put some backing b… Read More